T1	Participants 82 110	metastatic colorectal cancer
T2	Participants 282 495	patients with epidermal growth factor receptor-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
T3	Participants 831 859	metastatic colorectal cancer
T4	Participants 1728 1756	metastatic colorectal cancer
